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Abstract
Introduction Recent anticancer drugs have been made larger to
pass selectively through tumor vessels and stay in the
interstitium. Understanding drug movement in association with
its size at the single-molecule level and estimating the time
needed to reach the targeted organ is indispensable for
optimizing drug delivery because single cell-targeted therapy is
the ongoing paradigm. This report describes the tracking of
single solid nanoparticles in tumor xenografts and the estimation
of arrival time.
Methods Different-sized nanoparticles measuring 20, 40, and
100 nm were injected into the tail vein of the female Balb/c nu/
nu mice bearing human breast cancer on their backs. The
movements of the nanoparticles were visualized through the
dorsal skin-fold chamber with the high-speed confocal
microscopy that we manufactured.
Results An analysis of the particle trajectories revealed diffusion
to be inversely related to the particle size and position in the
tumor, whereas the velocity of the directed movement was
related to the position. The difference in the velocity was the
greatest for 40-nm particles in the perivascular to the
intercellular region: difference = 5.8 nm/s. The arrival time of
individual nanoparticles at tumor cells was simulated. The
estimated times for the 20-, 40-, and 100-nm particles to reach
the tumor cells were 158.0, 218.5, and 389.4 minutes,
respectively, after extravasation.
Conclusions This result suggests that the particle size can be
individually designed for each goal. These data and methods are
also important for understanding drug pharmacokinetics.
Although this method may be subject to interference by surface
molecules attached on the particles, it has the potential to
elucidate the pharmacokinetics involved in constructing novel
drug-delivery systems involving cell-targeted therapy.
Introduction
The strategies of recently developed cancer therapy are
designed to deliver sufficient doses of drugs to the target
tumor and to reduce any unnecessary damage to the normal
organs. The effects of numerous drugs have been maximized
by controlling their diameter to appropriate sizes to pass
selectively through the tumor vasculature. Tumors contain a
high density of dilated vessels with poor architecture [1],
which have larger pores than normal vessels and exhibit higher
permeability [2]. This characteristic contributes to higher con-
centrations of plasma macromolecular proteins in the tumor
interstitial space [3-6]. Once a drug is administered, it passes
through the vascular pores and thereafter must overcome
interstitial and intercellular barriers to approach malignant
cells. Interstitial drug transport is determined by both diffusion
and the directional flow, with a net flow of fluid from blood ves-
sels to the lymphatic system [7] influenced by components of
the tumor-specific extracellular matrix, notably collagens and
proteoglycans [8]. Large drugs in the interstitium are trans-
ported more slowly [9] and thus are retained in the interstitial
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space for longer periods [10]in vivo because the interstitial
matrix blocks drug movement [11,12]. The size dependency of
in vivo drug delivery in the tumor interstitium has been quanti-
tatively estimated by observing the average dispersion of
drugs [13]. However, these general observations cannot fully
explain the behavior of individual drugs, such as their binding
to the interstitial matrix and nonuniform movements. Con-
versely, single-particle tracking is a powerful method for gain-
ing unprecedented reductive information regarding individual
drug molecules, such as molecular motion in biophysics
[14,15] and the delivery processes of antibodies [16].
The present study focused on single-particle tracking to eluci-
date the influence of homogeneous size on the movement of
the nanoparticles in tumor xenograft. The sizes of the nanopar-
ticles for drug-delivery systems were optimized in relation to
the molecular size of the agent. Hence, the delivery processes
were clarified, and then these processes were quantitatively
analyzed to clarify the rate-limiting constraints for single-nano-
particle delivery in the interstitial space in vivo.
Materials and methods
Fluorescent beads and Quantum dot 705
"Fluospheres" were manufactured from high-quality ultraclean
polystyrene microspheres by Invitrogen Molecular Probes
(Eugene, OR, USA). Fluospheres [17] and Quantum dot 705
ITK kit (Quantum Dot Corp., Hayward, CA, USA) were useful
as markers during observations because of their intense
brightness. Quantum dot 705 was used for 20-nm nanoparti-
cles. Fluospheres of 40, 100, and 200 nm were selected,
emitting orange fluorescence (excitation/emission maxima at
540/560 nm). The diameter distributions of the beads were
very small at 100 ± 5 nm (<5% error) and 200 ± 10 nm (<5%
error). The zeta potentials, electricity of the inner area, and the
conceptual surface of Quantum dot, Fluospheres (40 nm and
100 nm) are -4.97 mV, -18.60 mV, and -33.73 mV, respec-
tively.
Cell line
The human breast cancer cell line KPL-4 [18] was kindly pro-
vided by Dr. J. Kurebayashi (Kawasaki Medical School,
Kurashiki, Japan). KPL-4 cells were cultured in Dulbecco's
Modified Eagles Medium (DMEM) supplemented with 5%
Fetal Bovine Serum (FBS).
Mouse model
A suspension of KPL-4 cells (1.0 × 107 cells/100 μl DMEM)
was subcutaneously transplanted into the dorsal skin of female
Balb/c nu/nu mice at 5 to 7 weeks of age (Charles River
Japan, Yokohama, Japan). Several weeks after the inoculation,
mice with tumor volumes of 100 to 200 mm3 were selected.
All mice were maintained in pathogen-free facilities. All opera-
tions were carried out in accordance with the Institutional Ani-
mal Use and Care Regulations of Tohoku University, after
receiving approval from the Committee on Animal Experi-
ments.
The mice were anesthetized with an intraperitoneal injection of
a mixture of ketamine and xylazine at doses of 95 and 5 mg/kg,
respectively. The temperature of the mice was maintained at
37°C by using an objective lens heater.
After imaging, the mice were killed with a CO2 overdose. The
tumors were removed and divided for histologic nanoparticle-
uptake studies 24 hours after the administration of the parti-
cles. The tumors were fixed in optimal cutting temperature
(OCT) compound (Sakura Finetek, Torrance, CA, USA), fro-
zen, cut into 6-μm sections, and either examined with confocal
microscopy or stained with hematoxylin and eosin and exam-
ined with bright-field microscopy.
Dorsal skin-fold chambers
Dorsal skin-fold chambers, which were described in a previous
study [19,20] and modified for the present study, were used
to fix the mouse tumors over the objective lens of an inverted
microscope [see Additional data file 1]. A sterilized polyvinyl
chloride plate with a small window was mounted on the stage
to fix the extended double layer of dorsal skin, including the
tumor. The skin was sutured with 5-0 nylon around the window
and fixed. A spatial accuracy of 30 nm was achieved. The beat-
ing of the heart and breathing have a serious influence on this
measurement. It was, therefore, necessary to cancel the heart-
beat and breathing by fixing. The tumor was exposed with oval
skin and subcutaneous incisions of ~10 mm in diameter and
then placed on a neutral saline-mounted coverslip (0.12 to
0.17 mm in thickness) on the viewing platform of the micro-
scope. The mouse was fixed on the stage to stabilize the
chamber [see Additional data file 2]. The tumors were thereaf-
ter directly visualized by using this set-up.
Figure 1
Normal and tumor vasculatures visualized by intravital imaging Normal and tumor vasculatures visualized by intravital imaging. An 
objective lens of 20× was used in this experiment. (a) Normal vessels 
are aligned parallel to each other. (b) Tumor vessels have chaotic char-
acteristics, such as uneven diameters and unparallel distribution. Scale 
bar, 100 μm.Available online http://breast-cancer-research.com/content/11/4/R43
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In vivo imaging and tracking
The optics system for the observations consisted primarily of
an epifluorescence microscope (IX71; Olympus, Tokyo,
Japan) with modifications [21,22], a Nipkow lens confocal unit
(CSU10; Yokokawa, Tokyo, Japan), and an electron multiplier
charge-coupled device (EMCCD) camera (iXon 887; Andor,
Tokyo, Japan) [see Additional data file 2]. The confocal unit
adopts multibeam scanning by using about 1,000 beams that
are simultaneously emitted through a pinhole disk to facilitate
high-speed scanning. The EMCCD has the advantage of offer-
ing unsurpassed sensitivity and has been shown to yield mark-
edly improved signal-to-noise ratios [23]. The objective lens
(×60; NA, 1.45) was moved by a piezo actuator with a feed-
back loop (Nano Control, Tokyo, Japan) to stabilize the posi-
tion of the focus. A computer controlled the piezo actuator in
synchronization with the image acquisitions, such that the
objective lens remained within the exposure time of the
EMCCD camera. An area of ~30 × 30 μm2 was illuminated by
a green laser (532 nm; Crystalaser, Reno, NV, USA). This sys-
tem can capture images of a single nanoparticle at a video rate
of 33 ms/frame.
The xy position of each fluorescent spot was calculated by fit-
ting to a two-dimensional gaussian curve. Single molecules
could be identified by their fluorescence intensities. The accu-
racy of the x and y directions of images taken at an exposure
time of 33 ms was 30 nm, while also taking the standard devi-
ation into consideration.
Calculations of the mean square displacements, 
diffusion coefficients
The trajectories were calculated by using MATLAB 6.0
Release 12 (The MathWorks Inc., Natick, MA, USA). The
mean square displacements (MSDs) of individual nanoparti-
cles were defined by the following equation:
where xi and yi are the positions on frame i, N is the total
number of frames, Δt is the time between frames and distance
between steps in time t [24], and nΔt is the time interval over
which the MSD is calculated. When the change in the MSD
was nonlinear over time, the curve could be fitted by the equa-
tion for confined diffusion [24,25]. For direct diffusion, in
which a nanoparticle moves in a direction at a constant drift
velocity with diffusion, the MSD plot is convex and closer to
time 0, where the change in the MSD was linear. Single-mole-
cule diffusion was considered to be brownian motion, and the
diffusion coefficient (D), representing the amount of substance
diffusing across an area through a unit concentration gradient
in unit time, was calculated according to the following equa-
tions:
Statistical analysis
All statistical analyses were carried out by using the StatMate
III software program (ATMS Co. Ltd., Tokyo, Japan). The
MSDs, velocities, and diffusion coefficients for the three differ-
ent-sized particles were compared with a two-way analysis of
variance (ANOVA). The correlations between the velocity, dif-
fusion coefficient, and position for the same particle were
determined by using the Spearman rank test. All probabilities
(P values) of the statistical tests were based on two-tailed
tests, and values of P < 0.05 were considered to indicate sta-
tistical significance.
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Histologic evaluation of extravasation of each nanoparticle Histologic evaluation of extravasation of each nanoparticle. Extravasa-
tion of single nanoparticles in mice with human tumor xenografts. (a, c, 
e) Hematoxylin and eosin-stained images observed by bright-field 
microscopy after injection of 40-, 100-, and 200-nm particles, respec-
tively. (b, d, f) Laser confocal microscopy images after injection of 40-, 
100-, and 200-nm particles, respectively. Particles of 40 nm (b) and 
100 nm (d) extravasated (arrows), whereas 200-nm nanoparticles did 
not extravasate (arrow) (f). Scale bar, 10 μm.Breast Cancer Research    Vol 11 No 4    Kawai et al.
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Results
Imaging of normal and tumor vasculatures
To visualize and confirm the macroscopic characteristics of
normal and tumor vasculatures, Quantum dot 705 (40 nmol/l
in 200-μl phosphate-buffered saline; PBS) was administered
into the tail vein of mice with human breast cancer xenografts
and observed with intravital confocal microscopy. In the nor-
mal vasculature, the blood vessels were parallel and straight
relative to one another (Figure 1a). In the tumor vasculature,
however, the blood vessels were chaotically disorientated with
uneven sizes (Figure 1b). A typical example of the pathologic
nature of the tumor vasculature is illustrated by the looped cha-
otic structure in the center of Figure 1b[26].
Histopathologic analysis of extravasation of single 
nanoparticle in tumor xenograft in mice
After the injection of nanoparticles, the tumors were fixed, cut
into 6-μm sections, and either examined with confocal micros-
copy or stained with hematoxylin and eosin and examined with
bright-field microscopy. Images of the tumors were taken to
allow observation of the nanoparticles in the tumor vessels and
interstitium (Figure 2a–f). Particles of 40 and 100 nm were
present in the interstitial region (arrows in Figure 2b and 2d,
respectively) in 20 visual fields. In contrast, 200-nm particles
were found only in the vessels (arrows), but not in the intersti-
tial region (Figure 2f).
Trajectories of single nanoparticles in perivascular, 
interstitial and intercellular areas
The injected nanoparticles circulated within the tumor vessels.
Some of the nanoparticles became extravasated and moved
into the perivascular area close to the tumor vessels. The ves-
sel boundaries were traced by accumulating all the acquired
images and were superimposed onto the actual trajectories of
the nanoparticles.
Suddenly after the injection, the nanoparticles appeared in the
tumor vasculature. As shown in Figure 3a, a 20-nm particle
was found to diffuse within a restricted area (~800 nm in diam-
eter) and then suddenly move to the next point. The acquired
trajectories of single particles of different sizes in the perivas-
cular area are shown in Figure 3b. For 20-nm particles, the
area of random diffusion composed only a small part of the
overall trajectory, whereas directed movement occupied the
main part. However, larger molecules showed increased ran-
dom diffusion.
At 2 hours after the injection, the migrated nanoparticles were
tracked in the tumor interstitial region. As shown in Figure 4a,
Figure 3
Trajectories of nanoparticles in the perivascular region Trajectories of nanoparticles in the perivascular region. The arrow indicates the direction of the movements of the nanoparticles. (a) Trajectories of 
the Quantum dot in the perivascular region. The trajectories are encoded on the time axis from blue to red. (b) Trajectories of three different-sized 
particles in the perivascular area.Available online http://breast-cancer-research.com/content/11/4/R43
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a 20-nm particle diffused within a highly restricted area,
although it appeared to be smaller than in the perivascular
region. In Figure 4b, diffusion contributed a much larger part
of the movement for 20-nm particles. For 40- and 100-nm par-
ticles, the movement appeared to be diffusional.
About 3 hours after the injection, the nanoparticles were seen
in the tumor intercellular region. The cell boundaries were
traced by accumulating all the acquired images and were
superimposed onto the actual trajectories. As shown in Figure
5a, a 20-nm particle movement appeared to be much smaller.
In Figure 5b, the proportion of diffusion of particles was
increased. The movements of 40- and 100-nm particles
appeared to represent only diffusion, indicating that these par-
ticles are under brownian motion.
Mean square displacements, velocities, and diffusion 
coefficients in different regions of tumors
The MSD was calculated by the positional data for each parti-
cle. The MSD plots of the particles in the perivascular, intersti-
tial, and intercellular regions are shown in Figures 6 through 8,
respectively.
The movement plots of the different-sized molecules in the
perivascular region were convex. The movements of each mol-
ecule were well fitted to curves, assuming directed movement
made by lymphatic flow from vasculature to lymphatic system
(Figure 6) with superimposed random diffusion [24] but not fit-
ted to either simple directed movement or random diffusion.
The R2 values of the fitted equations (dotted lines) were 0.98,
0.99, and 0.97 for 20-, 40-, and 100-nm particles, respec-
tively. In the interstitial region, the plots for the different-sized
molecules were also convex, which was similar to those in the
perivascular region, but the steepness of each of the three
curves was lower than the corresponding curve in the perivas-
cular region. The R2 values of the fitted equations were 1.00,
0.98, and 0.98 for 20-, 40-, and 100-nm particles, respec-
tively. The apparent values of the MSD plots in the intercellular
region were approximately half or one order of magnitude
lower than those in the other two regions. The R2 values of the
fitted equations (two-dimensional) were 0.97, 0.97, and 0.94
for 20-, 40-, and 100-nm particles, respectively.
The relations were analyzed between the velocities and diffu-
sion coefficients and the particle diameters and positions in
the tumor (perivascular, interstitial, and intercellular regions).
As shown in Figure 9a, the velocity changed in relation to the
particle position. Notably, the difference in velocity was greater
for 40-nm particles (from 9.7 nm/s in the perivascular region to
7.1 nm/s in the interstitial region and 3.9 nm/s in the intercel-
lular region) than for 20- and 100-nm particles and negatively
correlated with the position (correlation coefficient = -5.5; P <
Figure 4
Trajectories of nanoparticles in the interstitial region Trajectories of nanoparticles in the interstitial region. (a) Trajectories of the Quantum dot in the interstitial region. The trajectories are encoded on the 
time axis from blue to red to yellow. (b) Trajectories of three different-sized particles in the interstitial region.Breast Cancer Research    Vol 11 No 4    Kawai et al.
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0.001, Spearman rank test). The diameters of the particles
were not related to the velocities in the perivascular and inter-
stitial regions (n = 6, P = 0.39 for the perivascular region and
P = 0.14 for the interstitial region (two-way ANOVA test) but
were related to the velocities in the intercellular region (n = 6;
P = 0.016, two-way ANOVA test). All three curves were par-
allel, indicating an inverse relation with the diameter at intercel-
lular region. As shown in Figure 9b, the diffusion coefficients
of the three curves were convex, inversely related to the diam-
eter. Notably, a steep difference was found between the 20-
and 40-nm particles in the perivascular region (correlation
coefficient = -0.4; P < 0.001, Spearman rank test). For 20-nm
particles, a remarkable disparity was seen between the parti-
cle positions, especially in the perivascular and interstitial
Figure 5
Trajectories of nanoparticles in the intercellular region Trajectories of nanoparticles in the intercellular region. (a) Trajectories of the Quantum dot in the intercellular region. (b) Trajectories of three differ-
ent-sized particles in the intercellular region.
Figure 6
MSD plots of nanoparticles in the perivascular regions MSD plots of nanoparticles in the perivascular regions. Data represent 
the means (solid lines) and two-dimensional fitted curves (dotted lines) 
of particles.
Figure 7
MSD plots of nanoparticles in the interstitial regions MSD plots of nanoparticles in the interstitial regions. Data represent the 
means (solid lines) and two-dimensional fitted curves (dotted lines) of 
particles.Available online http://breast-cancer-research.com/content/11/4/R43
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regions. The diameters of the molecules in the perivascular
and interstitial regions were related to the diffusion coeffi-
cients (n = 6; P < 0.05 for two regions; two-way ANOVA test).
Discussion
The present study succeeded in clarifying the specific delivery
processes of single nanoparticles after injection into the mice
[16], as well as tracking and quantifying the detailed move-
ments of different-sized nanoparticles in the interstitium of
tumor xenograft. We clarified the specific behavior of the solid-
sized nanoparticle and the relations among the size, place,
velocities, and diffusion for the individual mechanisms in the
interstitial space for the first time at the single-particle level.
The structural characteristics of the tumor vasculature are
strongly related to the function of neovascularized tumor ves-
sels, because antiangiogenic agents have the potential to nor-
malize the tumor vasculature and to change the efficiency of
drug delivery [27]. The tumor vasculature of KPL-4 cancer
cells was visualized, because the characteristics of their neo-
vascularized vessels have not yet been clarified. Quantum dot
was used as the contrast agent because it has a stronger size
effect, thus enabling it to stay in the vessels for longer periods
than low-molecular-weight agents [28].
In previous studies, the movements of macromolecules have
been analyzed ex vivo [29] and in vivo [9]. These studies
made it possible to visualize several aggregated particles, but
not single particles. Conversely, single-particle tracking has
recently been applied to mice [16]. Our results regarding the
relation between the drug size and movements with single-par-
ticle tracking are important to design recently manufactured
nanocapsules such as polymeric micelles [30], liposomes
[31], and dendrimers [32]. These nanocapsules stay and
show their effect on the targeted tumor in a single particle, and
thus we can measure the precise point where these particles
show effects only with our single-particle tracking, not by the
previously mentioned method. Furthermore, the sizes of these
drugs are changeable by manufacturing procedures; we can
design their diameter to control the time that the drug shows
its effect on the tumor (we mention the calculated time in the
last paragraph in Discussion). Single-particle tracking is there-
fore considered to be important for the design of these drugs.
The movement of particles in each process was the sum of
random diffusions within a highly restricted area and directed
movements toward another area. These data show that the
velocities of the three different-sized particles decreased while
moving in the three regions in a parallel manner. The diffusion
Figure 9
Velocities and diffusion coefficients in different regions of tumors Velocities and diffusion coefficients in different regions of tumors. (a) Velocities relative to the particle diameters in different regions of tumors. (b) 
Diffusion coefficients relative to the particle diameters in different regions of tumors. Blue line: 20-nm; red line: 40-nm; green line: 100-nm, respec-
tively.
Figure 8
MSD plots of nanoparticles in the intercellular regions MSD plots of nanoparticles in the intercellular regions. Data represent 
the means (solid lines) and two-dimensional fitted curves (dotted lines) 
of particles.Breast Cancer Research    Vol 11 No 4    Kawai et al.
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coefficients were more significantly decreased according to
size in the perivascular region than in the other two regions. It
is generally thought that the tumor interstitium consists of a
collagenous cage structure containing viscous proteoglycans
[8] and that these matrices thus block drug movement
[11,12]. The data for the particle velocities are consistent with
previous data showing the velocity to be weakly dependent on
the particle size [8] and dependent on the decreasing intersti-
tial flow from the perivascular region [33,34] and that the dif-
fusion coefficients of particles are limited in proportion to the
particle sizes [35]. Others studies have shown that the extra-
cellular matrix collagen content is not related to particle speed
[35] but does restrict particle diffusion. The current data
appear to indicate that directional movement is disrupted by
the particle position, rather than the particle size, because the
three-dimensional structure of the collagenous matrix was suf-
ficiently loose to allow movements of the different-sized parti-
cles and free diffusion of the 20-nm particles in the
perivascular region, but limited the diffusion of particles larger
than 20 nm because of the presence of viscous hyaluronan.
Other vesicles, such as polyethylene glycolated (PEGylated)
materials, are used as drug carriers, but they are associated
with problems in drug release because of their stable struc-
ture; they also contain releasing drugs in themselves. The
solid-state carriers used in the current study can be made
functional by attaching molecules. Furthermore, the accumula-
tion of the conjugation and uptake of the Quantum dot-anti-
body complex in the tumor [16] could be detected. The
particle used in the present study can therefore be individually
detected, and the pore size can be estimated because of its
solidity. The time required for a drug to reach the tumor is an
important issue for measuring the time to show its effect. We
used these data to simulate the time required for a single
agent to reach a tumor cell after extravasation. Because many
anticancer drugs affect cancer cells at mitosis, 78.9 μm was
selected as the average distance between mitotic cells and
their adjacent microvessels in the tumor [36]. The perivascu-
lar, interstitial, and intercellular regions were assumed to be
equally distributed. After extravasation, the estimated times for
different particles of the 20-, 40-, and 100-nm particles to
reach the tumor were 140.0, 196.9, and 358.4 minutes for
2.25% of the particles; 158.0, 218.5, and 389.4 minutes for
50% of the particles; and 178.5, 242.6, and 423.1 minutes for
97.5% of the particles, respectively.
Conclusions
Elucidating the precise mechanism for interstitial movement of
nanoparticles in animal models of human breast cancer will
clarify the fundamental aspects of the drug-delivery process.
The method used in the present study could therefore be
potentially useful for drug design to increase the effectiveness
of tumor-targeting nanoparticles.
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